Recent Notable Cancer Research Discoveries: Advancements in Clinical Research
Keeping up with the latest cancer research discoveries is crucial for individuals interested in clinical advancements and treatment breakthroughs. In recent years, there have been remarkable developments in the field of cancer research, leading to improved diagnostic techniques, targeted therapies, and innovative treatment approaches. This blog highlights four notable discoveries from the past few years that have the potential to transform cancer care. These findings cover a range of cancer types and shed light on novel strategies for diagnosis, treatment, and prevention.
Liquid Biopsies:
Revolutionizing Cancer Diagnosis and Monitoring Liquid biopsies, a non-invasive approach to detect tumor-related genetic alterations in body fluids, have emerged as a promising tool for cancer diagnosis and monitoring. Recent research has demonstrated their effectiveness in detecting early-stage cancers, monitoring treatment response, and tracking the development of resistance (Wan et al., 2020). Liquid biopsies offer a less invasive alternative to traditional tissue biopsies and hold the potential to enable earlier detection and personalized treatment decisions.
Immunotherapy:
Enhancing the Body's Natural Defense Against Cancer Immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to target and eliminate cancer cells. Notable advancements include the development of immune checkpoint inhibitors, such as pembrolizumab (Keytruda) and nivolumab (Opdivo), which have shown remarkable success in treating a range of cancers, including melanoma, lung cancer, and bladder cancer (Gadgeel et al., 2019). These therapies work by releasing the brakes on the immune system, allowing it to recognize and attack cancer cells. Immunotherapy has significantly improved patient outcomes and offers new hope for those with advanced or refractory cancers.
Precision Medicine:
Tailoring Treatment to Genetic Alterations Precision medicine utilizes genomic profiling to identify specific genetic alterations in individual tumors and match patients with targeted therapies. The discovery of gene mutations, such as EGFR in non-small cell lung cancer, has led to the development of targeted therapies like osimertinib (Tagrisso) (Oxnard et al., 2018). Precision medicine has also shown promising results in other cancers, including breast, colorectal, and hematologic malignancies. By tailoring treatment to the genetic characteristics of each patient's tumor, precision medicine aims to improve treatment response rates and minimize side effects.
CAR-T Cell Therapy:
Revolutionizing Immunotherapy for Blood Cancers Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking treatment for certain types of blood cancers. CAR-T therapy involves modifying a patient's own T-cells to express specific receptors that target cancer cells. Notable successes include the use of CAR-T therapy in pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) (Maude et al., 2018). CAR-T therapy has also shown remarkable efficacy in treating refractory large B-cell lymphoma (Neelapu et al., 2017). These breakthroughs highlight the potential of CAR-T therapy to provide durable responses in patients with limited treatment options.
In recent years we have witnessed significant advancements in cancer research, with discoveries spanning liquid biopsies, immunotherapy, precision medicine, and CAR-T cell therapy. These breakthroughs offer new avenues for early detection, personalized treatment, and improved outcomes for cancer patients. As clinical research continues to evolve, it is essential for individuals interested in the field to stay informed about these notable discoveries to advocate for the best possible care and make informed decisions regarding cancer prevention, diagnosis, and treatment.
You can find
cancer clinical trials near you by browsing ClinicalConnection. To search all of our clinical trial listings in your area click the button below.
References:
Gadgeel, S. M., Rodríguez-Abreu, D., Speranza, G., Establishing sustained responses and long-term survival in patients with advanced non-small cell lung cancer: Updated results from KEYNOTE-189. Journal of Clinical Oncology, 37(15_suppl), 9013. doi:10.1200/JCO.2019.37.15_suppl.9013
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., ... & Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439-448. doi:10.1056/NEJMoa1709866
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., ... & Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2531-2544. doi:10.1056/NEJMoa1707447
Oxnard, G. R., Yang, J. C. H., Yu, H. A., Kim, S. W., Saka, H., Horn, L., ... & Dziadziuszko, R. (2018). TATTON Phase Ib Expansion Cohort: Osimertinib Plus Savolitinib for Patients with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI. Journal of Clinical Oncology, 36(15_suppl), 9004. doi:10.1200/JCO.2018.36.15_suppl.9004
Wan, J. C., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., & Pacey, S. (2020). Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nature Reviews Cancer, 17(4), 223-238. doi:10.1038/nrc.2016.14